Trilaciclib is under clinical development by G1 Therapeutics and currently in Phase III for Metastatic Colorectal Cancer. According to GlobalData, Phase III drugs for Metastatic Colorectal Cancer have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Trilaciclib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Trilaciclib (Cosela) is a potential antineoplastic agent with chemoprotective properties. It is formulated as lyophilized cake for solution for intravenous route of administration. Cosela is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).
Trilaciclib is under development for the treatment of small-cell lung cancer, metastatic bladder cancer (locally advanced or metastatic urothelial carcinoma), metastatic triple negative breast cancer, colon cancer, metastatic colorectal cancer, castrate-resistant prostate cancer, NSCLC as first line and chemotherapy-induced myelosuppression. It is administered through intravenous route. The drug candidate acts by targeting cyclin-dependent kinases (CDK) 4 and 6. It was also under development for the treatment of non-small cell lung cancer.
G1 Therapeutics overview
G1 Therapeutics is a biopharmaceutical company. It discovers, develops and commercializes therapeutics for the treatment of cancer. The company offers pipeline products that include COSELA (trilaciclib), a CDK4/6 inhibitor to preserve hematopoietic stem cell and immune system function during chemotherapy; G1T38, an oral CDK4/6 inhibitor served as backbone therapy for multiple combination regimens; Lerociclib; and G1T48, an oral selective estrogen receptor degrader. G1 Therapeutics discovers new small molecule-based methods that prevent the hematological side effects of cancer chemotherapy and exposure to ionizing radiation. The company also develops small molecules to target specific proteins associated with cell proliferation and growth. It operates through its laboratory located in Research Triangle Park. G1 Therapeutics is headquartered in Research Triangle Park, North Carolina, the US.
For a complete picture of Trilaciclib’s drug-specific PTSR and LoA scores, buy the report here.